Skip NavigationFDA Logo links to FDA home pageCenter for Devices and Radiological Health, U.S. Food and Drug AdministrationHHS Logo links to Department of Health and Human Services website
FDA Home Page | CDRH Home Page | Search | A-Z Index U.S. Food and Drug AdministrationCenter for Devices and Radiological Health Questions?
horizonal rule
(Logo Graphic) Office of In Vitro Diagnostic Device Evaluation and Safety OIVD


Search OIVD
 
   (Powered by Google)
(navigation menu)
  • All OIVD Products
  • 510(k) Database
  • PMA Database
  • CLIA Database
  • Home use/OTC tests
  • IVD Guidances
  • IVD Standards
  • CeSub Turbo 510(k)
     eSubmissions
(navigation menu)
Home Regulatory Assistance Home & Lab Tests About Us Other Resources Contact Us

Letter to bioMèrieux, Inc.

May 6, 2004

Via FedEx

Mr. Philipp Sans
President and CEO
bioMèrieux, Inc.
100 Rodolphe Street
Building 1300
Durham, NC 27712

Dear Mr. Sans:

This is in reference to your firm’s recall of the VITEK GPS-107 gram positive susceptibility card, lot B28E.

The Food and Drug Administration (FDA) has reviewed the information obtained from your firm concerning this matter. We have concluded that the defect, an unknown percentage of the affected lot was erroneously stamped with a card code that causes the VITEK reader to read the GPS-107 cards and report the results as if they were VITEK GPS-105 cards, exposed patients whose samples were analyzed by this device to a risk of potentially life threatening consequences due to inaccurate test results. We are, therefore, classifying your voluntary action as a Class I recall, and are assigning recall number
Z-0917-04 to it.

The seriousness of this defect requires level A (100%) effectiveness checks. Your firm should verify that every consignee has been notified of the recall. The physicians who ordered the tests affected by the device defect should be notified about the potential error on the reported results. This type of physician notification is usually conducted by the laboratory that used the defective devices since the laboratory has the information on the affected patients and their physicians. Your firm should work with the affected laboratories to facilitate the distribution of this notification. The need for retesting should be left at the physician’s discretion and any questions to this regard should be directed to you.

The Food and Drug Administration’s policy concerning recalls is located in Title 21, Code of Federal Regulations, Part 7. Information regarding your recall will be published in the weekly FDA Enforcement Report.

The Kansas District Office will remain in close contact with your firm regarding this recall until this matter is resolved.

Sincerely yours,

/S/

Daniel G. Schultz, MD
Acting Director
Center for Devices and Radiological Health

Cc:
Fax bioMèrieux President

Updated May 13, 2004

horizonal rule

CDRH Home Page | CDRH A-Z Index | Contact CDRH | Accessibility | Disclaimer
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | HHS Home Page

Center for Devices and Radiological Health / CDRH